Pembrolizumab improves on chemo in MSI-H/dMMR mCRC

CLL14: Venetoclax plus obinutuzumab in untreated CLL

CHRONOS: Anti-EGFR rechallenge therapy with panitumumab driven by ctDNA molecular selection in mCC

Tislelizumab in oesophageal cancer after systemic therapy

HCRN GU 16-257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in MIBC patients

CheckMate067 outcomes: Nivolumab plus ipilimumab in advanced melanoma

LEAP-004: Lenvatinib + pembrolizumab for patients with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor

Highlights from ASCO 2021

OncoAlert and ecancer ASCO roundup - Day 3

OncoAlert and ecancer ASCO roundup - Day 1

NIVO plus chemo vs chemo alone as neoadjuvant treatment for patients with resectable NSCLC

Nivolumab plus ipilimumab or NIVO plus chemo versus chemo as firstline for advanced ESCC